Parathyroid hormone-related protein(50-69) and response to pamidronate therapy for tumour-induced hypercalcaemia

D J Dodwell, S K Abbas, A R Morton, A Howell

Research output: Contribution to journalArticlepeer-review


A region-specific radioimmunoassay has been employed to measure levels of immunoreactive parathyroid hormone-related protein(50-69) (iPTHrP(50-69)) in patients with tumour-induced hypercalcaemia (TIH). This assay is based on an antiserum raised against synthetic human PTHrP(50-69). The assay showed no cross-reactivity with human or bovine parathyroid hormone(1-84). The effect of a single dose (60 mg) of pamidronate was studied in 25 consecutive patients with TIH. All were rehydrated prior to treatment. All but 2 patients (8%) became normocalcaemic after treatment; both of these had very high levels of iPTHrP(50-69). Time to achieve normocalcaemia, as an index of relative resistance to pamidronate, correlated positively with pretreatment level of iPTHrP(50-69). Absence of radiological evidence of bone metastases also predicted relative resistance to pamidronate. In this study, iPTHrP(50-69)-induced osteoclastic bone resorption was a more important mechanism in the causation of TIH than PTHrP-induced renal reabsorption of calcium as assessed by the renal thresholds for calcium and phosphate.

Original languageEnglish
Pages (from-to)1629-33
Number of pages5
JournalEuropean journal of cancer (Oxford, England : 1990)
Issue number12
Publication statusPublished - Dec 1991


  • Adult
  • Aged
  • Aged, 80 and over
  • Bone Neoplasms
  • Breast Neoplasms
  • Diphosphonates
  • Female
  • Humans
  • Hypercalcemia
  • Lung Neoplasms
  • Lymphoma, Non-Hodgkin
  • Male
  • Middle Aged
  • Parathyroid Hormone
  • Parathyroid Hormone-Related Protein
  • Proteins
  • Journal Article


Dive into the research topics of 'Parathyroid hormone-related protein(50-69) and response to pamidronate therapy for tumour-induced hypercalcaemia'. Together they form a unique fingerprint.

Cite this